A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics

November 1, 2016 updated by: Hoffmann-La Roche

Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish "Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma" Study

This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

32277

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Adana, Turkey, 01330
      • Adana, Turkey, 01220
      • Afyon, Turkey, 03200
      • Ankara, Turkey, 06100
      • Ankara, Turkey, 06500
      • Ankara, Turkey, 06800
      • Ankara, Turkey, 06280
      • Ankara, Turkey, 06200
      • Baıkesir, Turkey, 10000
      • Bursa, Turkey, 16059
      • Bursa, Turkey, 16040
      • Denizli, Turkey, 20070
      • Diyarbakir, Turkey, 21280
      • Edirne, Turkey, 22770
      • Erzurum, Turkey, 25050
      • Gaziantep, Turkey, 27100
      • Isparta, Turkey, 32260
      • Istanbul, Turkey, 34000
      • Istanbul, Turkey, 34300
      • Istanbul, Turkey, 34890
      • Istanbul, Turkey, 34093
      • Istanbul, Turkey, 34020
      • Izmir, Turkey, 35100
      • Izmir, Turkey, 35340
      • Izmir, Turkey, 35110
      • Kayseri, Turkey, 38039
      • Konya, Turkey, 42080
      • Malatya, Turkey, 44280
      • Sıhhiye, ANKARA, Turkey, 06100
      • Tokat, Turkey, 60250
      • Trabzon, Turkey, 61080

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Participants with non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey

Description

Inclusion Criteria:

  • Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma
  • Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer

Exclusion Criteria:

  • Participants not living in the city or representative region of the study center

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Participants With Cancer
Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
Time Frame: 36 months
36 months
Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region
Time Frame: 36 months
36 months
Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
Time Frame: 36 months
36 months
Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
Time Frame: 36 months
36 months
Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
Time Frame: 36 months
36 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall Survival (OS)
Time Frame: 36 months
36 months
Percentage of Participants Categorized by Tumor Size
Time Frame: 36 months
36 months
Percentage of Participants Categorized by Histopathology Diagnosis
Time Frame: 36 months
36 months
Percentage of Participants Categorized by the Staging System
Time Frame: 36 months
36 months
Percentage of Participants Categorized by Surgery Type
Time Frame: 36 months
36 months
Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)
Time Frame: 36 months
36 months
Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy)
Time Frame: 36 months
36 months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: 36 months
36 months
Percentage of Participants With Family History of Cancer and Other Conditions
Time Frame: 36 months
36 months
Percentage of Participants With History of Another Primary Cancer
Time Frame: 36 months
36 months
Percentage of Participants Categorized by Diagnostic Methods
Time Frame: 36 months
36 months
Percentage of Participants With Metastasis
Time Frame: 36 months
36 months
Percentage of Participants Categorized by Tumor Localization
Time Frame: 36 months
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hoffmann-La Roche

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

October 1, 2015

Study Completion (Actual)

October 1, 2015

Study Registration Dates

First Submitted

January 18, 2013

First Submitted That Met QC Criteria

January 24, 2013

First Posted (Estimate)

January 25, 2013

Study Record Updates

Last Update Posted (Estimate)

November 2, 2016

Last Update Submitted That Met QC Criteria

November 1, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ML28579

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe